1. Academic Validation
  2. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

  • PLoS One. 2018 May 3;13(5):e0196761. doi: 10.1371/journal.pone.0196761.
Anne Walter 1 2 Apirat Chaikuad 3 4 Renate Helmer 1 Nadège Loaëc 5 Lutz Preu 1 Ingo Ott 1 2 Stefan Knapp 3 4 Laurent Meijer 5 Conrad Kunick 1 2
Affiliations

Affiliations

  • 1 Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Braunschweig, Germany.
  • 2 Center of Pharmaceutical Engeneering (PVZ), Technische Universität Braunschweig, Braunschweig, Germany.
  • 3 Structural Genomics Consortium, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
  • 4 Institute for Pharmaceutical Chemistry, Structural Genomics Consortium and Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
  • 5 ManRos Therapeutics, Hôtel de Recherche, Centre de Perharidy, Roscoff, France.
Abstract

Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regulation of splicing by phosphorylation of SR-proteins and other splicing factors. Although compounds acting against CLKs have been described, only a few show selectivity against dual-specificity tyrosine phosphorylation regulated-kinases (DYRKs). We here report a novel CLK Inhibitor family based on a 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one core scaffold. Within the series, 3-(3-chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (KuWal151) was identified as inhibitor of CLK1, CLK2 and CLK4 with a high selectivity margin towards DYRK kinases. The compound displayed a potent antiproliferative activity in an array of cultured Cancer cell lines. The X-ray structure analyses of three members of the new compound class co-crystallized with CLK proteins corroborated a molecular binding mode predicted by docking studies.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-125202
    CLK1/CLK2/CLK4 Inhibitor